Janssen whizzes promising CLL agent over to regulators Medical Marketing and Media Gilead's candidate, idelalisib, was tested in combination with rituximab in treatment-naïve patients with CLL. That regimen achieved a compete response rate of 19% and an overall response rate of 97% in patients. AbbVie's contender, ABT-199, which Yee ... |
